Periventricular Nodular Heterotopia 8

Mendelian MONDO:0032588 Pathograph 9 Show in embeddings browser Periventricular Nodular Heterotopia

Periventricular nodular heterotopia 8 (PVNH8) is the periventricular nodular heterotopia form of the autosomal dominant ARF1-related neurodevelopmental disorder. ARF1 encodes ADP-ribosylation factor 1, a small GTPase that cycles between GDP- and GTP-bound states to drive COPI-vesicle coat assembly and membrane traffic at the Golgi apparatus; it is activated by the guanine nucleotide exchange factor ARFGEF2, whose own loss causes an autosomal recessive form of periventricular heterotopia. Disease variants disrupt the ARF1 GTPase cycle and the Golgi apparatus, impairing the vesicle trafficking and cell-cell adhesion that maintain apical radial-glial / neuroependymal integrity at the ventricular surface, so neurons fail to initiate migration from the periventricular germinal zone and remain as nodules of gray matter lining the lateral ventricles. The broader phenotype is dominated by intellectual disability, with variable microcephaly, seizures, corpus callosum abnormalities, hypotonia, and sensorineural/visual impairment; periventricular nodular heterotopia itself is a variable (minority) feature across the reported cohort rather than an obligate finding. Most variants are de novo, though inherited transmission with markedly variable expressivity has been documented.

Ask OpenScientist

Ask a research question about Periventricular Nodular Heterotopia 8. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

1
Autosomal Dominant HP:0000006
PVNH8 follows autosomal dominant inheritance. Most reported ARF1 variants are de novo, but an inherited variant with markedly variable expressivity has been documented, where a mildly affected father transmitted the variant to a daughter with intellectual disability and periventricular nodular heterotopia.
Autosomal dominant inheritance Expressivity: VARIABLE
Show evidence (2 references)
PMID:37185208 SUPPORT Human clinical
"De novo variants (10 missense, 1 frameshift, 1 splice altering resulting in 9 residues insertion) in ARF1 were identified among 17 unrelated individuals."
Establishes that ARF1 disease variants are predominantly de novo across an international cohort.
PMID:34353862 SUPPORT Human clinical
"We report the first inherited variant of ARF1 in a girl with intellectual disability and periventricular nodular heterotopia who inherited the variant from the father with previously undiagnosed single nodular heterotopia and mild clinical expression."
Documents inherited transmission with variable clinical expressivity, supporting autosomal dominant inheritance.
?

Discussions and Knowledge Gaps

1
Does the ARF1-related disorder arise from ARF1 haploinsufficiency (loss of function) or from constitutive activation (gain of function) of the ARF1 GTPase?
CONTROVERSY OPEN controversy_arf1_haploinsufficiency_vs_constitutive_activation
Attached to
pathophysiology#ARF1 GTPase Cycle Dysregulation
The first clinical report framed the mechanism as haploinsufficiency, citing an inherited loss-type variant with variable expressivity. The functional data are directly contradictory for the recurrent p.R99H variant: one group's GST-GGA3 pulldown found that the patient variants caused a significant decrease in active ARF1 (a loss-of-function reading), whereas another group found the same variant has increased GDP/GTP exchange, tighter effector binding, resistance to brefeldin A, and Golgi swelling - the signature of constitutive activation. Both readings converge on Golgi disruption and impaired neuronal migration, so the downstream pathograph is unaffected, but the allele-level mechanism (and therefore the expected effect of truncating versus missense variants) is unresolved.
Show evidence (3 references)
PMID:34353862 SUPPORT Human clinical
"haploinsufficiency of this gene causes a recognisable neurological disorder with abnormal neuronal migration and variable clinical expressivity."
States the haploinsufficiency (loss-of-function) interpretation.
PMID:37185208 SUPPORT In vitro / ex vivo
"were evaluated by the functional pulldown assay all caused a significant decrease in ARF1 activity (figure 2, p<0.05)."
A functional pulldown of five patient variants (including R99H) found decreased active ARF1, supporting the loss-of-function reading.
PMID:36345169 REFUTE In vitro / ex vivo
"indicating that the pathogenetic mechanism of the R99H-ARF1 variant involves constitutive activation with resultant Golgi and endosomal alterations."
Functional evidence for constitutive activation of the same R99H variant, contradicting the loss-of-function reading.
⚙

Pathophysiology

4
ARF1 GTPase Cycle Dysregulation
ARF1 is a small GTPase that acts as a molecular switch at the Golgi, inactive when bound to GDP and active when bound to GTP. Heterozygous disease variants disrupt this cycle, but the direction of the functional effect is contested: for the same recurrent p.R99H variant one study found a decreased level of steady-state active (GTP-bound) ARF1, while others found increased GDP/GTP exchange and constitutive activation. The readings converge on Golgi disruption regardless (see the mechanism controversy in discussions).
Genetic context variant_origin: GERMLINE
GTPase activity GO:0003924 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves GTPase activity (GO:0003924). GO:0003924 is a molecular function from the Gene Ontology.
Downstream
Golgi Vesicular Trafficking Failure
Show evidence (1 reference)
PMID:39052890 SUPPORT In vitro / ex vivo
"ARF1-p.R19C, -p.F51L, -p.R99C and -p.R99H exhibit higher GDP/GTP exchange activity compared to ARF1 wild type (WT)."
Biochemical assay shows disease variants dysregulate the ARF1 GTPase cycle.
Golgi Vesicular Trafficking Failure
Dysregulated ARF1 disrupts COPI-dependent vesicular transport at the Golgi apparatus. Expression of disease variants causes swelling and expansion of the Golgi in cultured cells and in migrating cortical neurons.
Golgi vesicle transport GO:0048193 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Golgi vesicle transport (GO:0048193). GO:0048193 is a biological process from the Gene Ontology.
Downstream
Radial Glial and Neuroependymal Integrity Failure
Show evidence (2 references)
PMID:36345169 SUPPORT In vitro / ex vivo
"the expression of this variant caused swelling of the Golgi apparatus"
Demonstrates Golgi structural disruption by a pathogenic ARF1 variant in cultured cells.
PMID:39052890 SUPPORT Model organism
"Expression of these variants resulted in the expansion of the Golgi apparatus in migrating cortical neurons."
Shows Golgi disruption in migrating cortical neurons in vivo.
Radial Glial and Neuroependymal Integrity Failure
Impaired vesicle trafficking and cell-cell adhesion compromise the apical attachment of radial glial cells and the integrity of the neuroependymal lining at the ventricular surface, the scaffold on which neurons migrate.
radial glial cell CL:0000681 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves radial glial cell (CL:0000681). CL:0000681 is a cell type from the Cell Ontology.
Downstream
Neuronal Migration Failure
Show evidence (2 references)
PMID:34353862 SUPPORT BACKGROUND Human clinical
"The primary anatomical defect leading to periventricular nodular heterotopia occurs within the neural progenitors along the neuroepithelial lining of the lateral ventricles and results from a defect in the initiation of neuronal migration, following disruption of the neuroependyma and impaired..."
Places the anatomical defect at the neuroependymal lining of the lateral ventricles.
PMID:24089482 SUPPORT Model organism
"coordinated interactions between actin (through FlnA) and vesicle trafficking (through Big2-Arf) direct the assembly and disassembly of membrane protein complexes required for neuronal migration and neuroependymal integrity."
Establishes Arf1-dependent trafficking as required for neuroependymal integrity in a mouse model.
Neuronal Migration Failure
Neurons fail to initiate migration from the periventricular germinal zone to the cortical plate, arresting as nodules along the lateral ventricle walls.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
neuron migration GO:0001764 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased neuron migration (GO:0001764). GO:0001764 is a biological process from the Gene Ontology.
Downstream
Periventricular nodular heterotopia
Polymicrogyria
Show evidence (2 references)
PMID:39052890 SUPPORT Model organism
"In utero electroporation-mediated gene transfer into the cortical neurons of embryonic mice demonstrated that p.R99C, p.R99H and p.K127E cause a migration defect."
Direct in vivo demonstration that ARF1 disease variants cause a neuronal migration defect.
PMID:24089482 SUPPORT Model organism
"Loss of Arf1 activity disrupts neuronal migration and cell adhesion."
Independent model-organism evidence that disrupted Arf1 activity impairs neuronal migration.
⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Periventricular Nodular Heterotopia 8 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

16
Ear 1
Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"Visual or hearing impairments were common (58%; 11/19), and included bilateral profound sensorineural hearing loss, cortical vision impairment, strabismus, astigmatism and hyperopia."
Reports sensorineural hearing loss among the common sensory impairments in the cohort.
Head and Neck 2
Microcephaly FREQUENT HP:0000252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Microcephaly (HP:0000252). HP:0000252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"Microcephaly below 3 SD was noted in 10 individuals (50%; 10/20)"
Microcephaly was present in half of the cohort.
Micrognathia OCCASIONAL HP:0000347 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Micrognathia (HP:0000347). HP:0000347 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"included micrognathia or retrognathia (26%; 5/19)"
Micrognathia/retrognathia was the recurrent facial feature in the cohort.
Musculoskeletal 2
Hypotonia FREQUENT HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:37185208 SUPPORT Human clinical
"Hypotonia | 68% | 12/17"
Hypotonia was present in 68% (12/17) of the cohort.
PMID:36345169 SUPPORT Human clinical
"associated with developmental delay, hypotonia, intellectual disability and motor stereotypies."
Reports hypotonia in a patient with a pathogenic ARF1 variant.
Spasticity OCCASIONAL HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"Spasticity | 25% | 4/17"
Spasticity occurred in 25% (4/17) of the cohort.
Nervous System 10
Periventricular nodular heterotopia OCCASIONAL HP:0032388 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Periventricular nodular heterotopia (HP:0032388). HP:0032388 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"Microcephaly below 3 SD was noted in 10 individuals (50%; 10/20), seizures of various types were reported in 8 (50%; 8/16) and PVNH in 3 (20%, 3/15)."
Reports periventricular nodular heterotopia in 3/15 (20%) of the cohort.
Intellectual disability VERY_FREQUENT HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"All individuals with available information presented with varying degrees of ID, ranging from mild to severe."
Intellectual disability was present in all individuals with available information.
Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36345169 SUPPORT Human clinical
"associated with developmental delay, hypotonia, intellectual disability and motor stereotypies."
Reports developmental delay in a patient with a pathogenic ARF1 variant.
Seizures FREQUENT HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"seizures of various types were reported in 8 (50%; 8/16)"
Seizures occurred in half of the assessable cohort.
Hypoplasia of the corpus callosum FREQUENT HP:0002079 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypoplasia of the corpus callosum (HP:0002079). HP:0002079 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36345169 SUPPORT Human clinical
"Neuroimaging revealed a hypoplastic corpus callosum and subcortical white matter abnormalities."
Documents hypoplastic corpus callosum in a patient with a pathogenic ARF1 variant.
PMID:37185208 SUPPORT Human clinical
"corpus callosum abnormalities (50%; 10/20)"
Corpus callosum abnormalities were among the most frequent MRI findings in the cohort.
Polymicrogyria HP:0002126 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Polymicrogyria (HP:0002126). HP:0002126 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"neuronal migration defects including PVNH, cortical dysplasia, polymicrogyria (45%; 9/20) and corpus callosum abnormalities (50%; 10/20)"
Polymicrogyria was among the neuronal migration defects seen on brain MRI.
Delayed speech and language development VERY_FREQUENT HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"Speech delay | 100% | 17/17"
Speech delay was universal (17/17) in the cohort.
Attention deficit hyperactivity disorder HP:0007018 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Attention deficit hyperactivity disorder (HP:0007018). HP:0007018 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"ADHD, autism | 50% | 6/11"
The cohort reported ADHD and autism together as a behavioral category in 50% (6/11); frequency is omitted here because the figure is combined.
Autism HP:0000717 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autism (HP:0000717). HP:0000717 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"ADHD, autism | 50% | 6/11"
The cohort reported ADHD and autism together as a behavioral category in 50% (6/11); frequency is omitted here because the figure is combined.
Ataxia OCCASIONAL HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"Ataxia | 21% | 4/17"
Ataxia occurred in 21% (4/17) of the cohort.
Growth 1
Growth delay OCCASIONAL HP:0001510 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Growth delay (HP:0001510). HP:0001510 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"Growth delay | 25% | 4/16"
Growth delay occurred in 25% (4/16) of the cohort.
🧬

Genetic Associations

1
ARF1
Gene: ARF1 hgnc:652 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ARF1 (hgnc:652). hgnc:652 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"We confirm the role of ARF1 in an autosomal dominant syndrome with a phenotypic spectrum including severe ID, microcephaly, seizures and PVNH due to impaired neuronal migration."
Confirms ARF1 as the autosomal dominant causative gene.
Variants (2)
p.Arg99His Pathogenic
Recurrent de novo missense variant (c.296G>A; p.R99H) identified in multiple unrelated individuals, and the variant carrying the most functional data. Those data conflict: some studies report increased GDP/GTP exchange, tighter binding to the effector GGA3 and constitutive activation, while another reports a decreased level of steady-state active ARF1 (the mechanism controversy recorded in discussions). They agree it disrupts the Golgi and causes a neuronal migration defect; notably one R99H individual did not have periventricular nodular heterotopia.
Show evidence (2 references)
PMID:36345169 SUPPORT Human clinical
"we report a pediatric patient with an ARF1-related disorder because of a monoallelic de novo missense variant (c.296 G > A; p.R99H) in the ARF1 gene, associated with developmental delay, hypotonia, intellectual disability and motor stereotypies."
Identifies the recurrent de novo p.R99H variant and its clinical features in a patient.
PMID:36345169 SUPPORT Human clinical
"The absence of periventricular nodular heterotopias in this R99H-ARF1 subject also indicates that this finding may not be a consistent phenotypic expression of all ARF1-related disorders."
Shows PVNH is not an obligate feature even for the recurrent R99H variant.
p.Leu170Pro Likely pathogenic
De novo missense variant (c.509T>C; p.Leu170Pro) reported in the first Chinese individual with ARF1-related disease, who presented with drug-refractory focal epilepsy and mild developmental delay but no periventricular nodular heterotopia. Molecular modelling and co-immunoprecipitation indicate it weakens the ARF1-GGA3 effector interaction, reinforcing that PVNH is not an obligate feature.
Show evidence (2 references)
PMID:40689678 SUPPORT Human clinical
"A de novo variant, c.509T > C (p.Leu170Pro), was detected in the ARF1 gene"
Identifies the de novo p.Leu170Pro variant in the first reported Chinese case.
PMID:40689678 SUPPORT In vitro / ex vivo
"results suggest that ARF1 variation may affect the interaction with GGA3."
Co-immunoprecipitation indicates the variant impairs the ARF1-GGA3 effector interaction.
💊

Medical Actions

2
Anti-seizure medication
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Small molecule
Symptomatic anti-seizure pharmacotherapy for the epilepsy. The course can be drug-resistant, as in the first Chinese case where several agents failed before seizure control was achieved.
Show evidence (1 reference)
PMID:40689678 SUPPORT Human clinical
"these medications proved to be ineffective in controlling the seizures"
Documents anti-seizure pharmacotherapy and its drug-resistant course in an ARF1 patient.
Developmental and rehabilitative therapy
Action: RehabilitationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Rehabilitation (NCIT:C15315). NCIT:C15315 is a clinical intervention from the NCI Thesaurus. NCIT:C15315
Platform: Behavioral / lifestyle
Supportive developmental, physical, and educational therapy for the intellectual disability, developmental delay, and motor impairment. No disease-modifying therapy exists; management is symptomatic and supportive.
🔬

Diagnosis

2
Brain MRI
Brain MRI demonstrates the periventricular nodular heterotopia and the other neuronal migration abnormalities that define the disorder.
brain magnetic resonance imaging NCIT:C16809 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:37185208 SUPPORT Human clinical
"MRI of the brain frequently showed abnormalities consistent with a neuronal migration disorder."
Brain MRI reveals the neuronal migration abnormalities central to the diagnosis.
Exome sequencing
Molecular diagnosis is established by identifying a pathogenic ARF1 variant, typically via trio exome or genome sequencing.
trio exome sequencing NCIT:C101295 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:40689678 SUPPORT Human clinical
"The genetic aetiology was elucidated through exome sequencing of the pedigree."
Exome sequencing of the pedigree identified the causal ARF1 variant.
{ }

Source YAML

click to show 
name: Periventricular Nodular Heterotopia 8
category: Mendelian
creation_date: "2026-10-25T00:00:00Z"
synonyms:
- PVNH8
- ARF1-related periventricular nodular heterotopia
- ARF1-related neurodevelopmental disorder
- ARF1-related disorder
description: >-
  Periventricular nodular heterotopia 8 (PVNH8) is the periventricular nodular
  heterotopia form of the autosomal dominant ARF1-related neurodevelopmental
  disorder. ARF1 encodes ADP-ribosylation factor 1, a small GTPase that cycles
  between GDP- and GTP-bound states to drive COPI-vesicle coat assembly and
  membrane traffic at the Golgi apparatus; it is activated by the guanine
  nucleotide exchange factor ARFGEF2, whose own loss causes an autosomal
  recessive form of periventricular heterotopia. Disease variants disrupt the
  ARF1 GTPase cycle and the Golgi apparatus, impairing the vesicle trafficking
  and cell-cell adhesion that maintain apical radial-glial / neuroependymal
  integrity at the ventricular surface, so neurons fail to initiate migration
  from the periventricular germinal zone and remain as nodules of gray matter
  lining the lateral ventricles. The broader phenotype is dominated by
  intellectual disability, with variable microcephaly, seizures, corpus callosum
  abnormalities, hypotonia, and sensorineural/visual impairment; periventricular
  nodular heterotopia itself is a variable (minority) feature across the reported
  cohort rather than an obligate finding. Most variants are de novo, though
  inherited transmission with markedly variable expressivity has been documented.
disease_term:
  preferred_term: periventricular nodular heterotopia 8
  term:
    id: MONDO:0032588
    label: periventricular nodular heterotopia 8
parents:
- Periventricular Nodular Heterotopia
notes: >-
  No GeneReviews chapter exists for ARF1-related disorder / PVNH8 (checked
  2026-10 via the committed Bookshelf index and a PubMed genereviews[book] title
  search). The disorder is MONDO-named for the periventricular nodular
  heterotopia feature, but the ARF1-related phenotype is broader than PVNH, which
  was present in only 3/15 of the best-phenotyped cohort (PMID:37185208).
inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  expressivity: VARIABLE
  description: >-
    PVNH8 follows autosomal dominant inheritance. Most reported ARF1 variants are
    de novo, but an inherited variant with markedly variable expressivity has
    been documented, where a mildly affected father transmitted the variant to a
    daughter with intellectual disability and periventricular nodular heterotopia.
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "De novo variants (10 missense, 1 frameshift, 1 splice altering resulting in 9 residues insertion) in ARF1 were identified among 17 unrelated individuals."
    explanation: Establishes that ARF1 disease variants are predominantly de novo across an international cohort.
  - reference: PMID:34353862
    reference_title: "ARF1 haploinsufficiency causes periventricular nodular heterotopia with variable clinical expressivity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report the first inherited variant of ARF1 in a girl with intellectual disability and periventricular nodular heterotopia who inherited the variant from the father with previously undiagnosed single nodular heterotopia and mild clinical expression."
    explanation: Documents inherited transmission with variable clinical expressivity, supporting autosomal dominant inheritance.
pathophysiology:
- name: ARF1 GTPase Cycle Dysregulation
  biological_scale: MOLECULAR
  description: >-
    ARF1 is a small GTPase that acts as a molecular switch at the Golgi, inactive
    when bound to GDP and active when bound to GTP. Heterozygous disease variants
    disrupt this cycle, but the direction of the functional effect is contested:
    for the same recurrent p.R99H variant one study found a decreased level of
    steady-state active (GTP-bound) ARF1, while others found increased GDP/GTP
    exchange and constitutive activation. The readings converge on Golgi
    disruption regardless (see the mechanism controversy in discussions).
  genetic_context:
    variant_origin: GERMLINE
  molecular_functions:
  - preferred_term: GTPase activity
    term:
      id: GO:0003924
      label: GTPase activity
  evidence:
  - reference: PMID:39052890
    reference_title: "Variations associated with neurodevelopmental disorders affect ARF1 function and cortical development."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ARF1-p.R19C, -p.F51L, -p.R99C and -p.R99H exhibit higher GDP/GTP exchange activity compared to ARF1 wild type (WT)."
    explanation: Biochemical assay shows disease variants dysregulate the ARF1 GTPase cycle.
  downstream:
  - target: Golgi Vesicular Trafficking Failure
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36345169
      reference_title: "A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "indicating that the pathogenetic mechanism of the R99H-ARF1 variant involves constitutive activation with resultant Golgi and endosomal alterations."
      explanation: Links the ARF1 variant directly to Golgi and endosomal disruption.
- name: Golgi Vesicular Trafficking Failure
  biological_scale: CELLULAR
  description: >-
    Dysregulated ARF1 disrupts COPI-dependent vesicular transport at the Golgi
    apparatus. Expression of disease variants causes swelling and expansion of
    the Golgi in cultured cells and in migrating cortical neurons.
  biological_processes:
  - preferred_term: Golgi vesicle transport
    modifier: DECREASED
    term:
      id: GO:0048193
      label: Golgi vesicle transport
  evidence:
  - reference: PMID:36345169
    reference_title: "A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the expression of this variant caused swelling of the Golgi apparatus"
    explanation: Demonstrates Golgi structural disruption by a pathogenic ARF1 variant in cultured cells.
  - reference: PMID:39052890
    reference_title: "Variations associated with neurodevelopmental disorders affect ARF1 function and cortical development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Expression of these variants resulted in the expansion of the Golgi apparatus in migrating cortical neurons."
    explanation: Shows Golgi disruption in migrating cortical neurons in vivo.
  downstream:
  - target: Radial Glial and Neuroependymal Integrity Failure
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24089482
      reference_title: "Filamin A regulates neuronal migration through brefeldin A-inhibited guanine exchange factor 2-dependent Arf1 activation."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Arf1 is required for maintenance of cell-cell junction connectivity and focal adhesion assembly."
      explanation: Links Arf1-dependent trafficking to the cell-adhesion junctions that maintain neuroependymal integrity.
- name: Radial Glial and Neuroependymal Integrity Failure
  biological_scale: CELLULAR
  description: >-
    Impaired vesicle trafficking and cell-cell adhesion compromise the apical
    attachment of radial glial cells and the integrity of the neuroependymal
    lining at the ventricular surface, the scaffold on which neurons migrate.
  cell_types:
  - preferred_term: radial glial cell
    term:
      id: CL:0000681
      label: radial glial cell
  evidence:
  - reference: PMID:34353862
    reference_title: "ARF1 haploinsufficiency causes periventricular nodular heterotopia with variable clinical expressivity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "The primary anatomical defect leading to periventricular nodular heterotopia occurs within the neural progenitors along the neuroepithelial lining of the lateral ventricles and results from a defect in the initiation of neuronal migration, following disruption of the neuroependyma and impaired neuronal motility."
    explanation: Places the anatomical defect at the neuroependymal lining of the lateral ventricles.
  - reference: PMID:24089482
    reference_title: "Filamin A regulates neuronal migration through brefeldin A-inhibited guanine exchange factor 2-dependent Arf1 activation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "coordinated interactions between actin (through FlnA) and vesicle trafficking (through Big2-Arf) direct the assembly and disassembly of membrane protein complexes required for neuronal migration and neuroependymal integrity."
    explanation: Establishes Arf1-dependent trafficking as required for neuroependymal integrity in a mouse model.
  downstream:
  - target: Neuronal Migration Failure
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34353862
      reference_title: "ARF1 haploinsufficiency causes periventricular nodular heterotopia with variable clinical expressivity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "results from a defect in the initiation of neuronal migration, following disruption of the neuroependyma and impaired neuronal motility."
      explanation: Asserts that neuroependymal disruption precedes and causes the migration defect.
- name: Neuronal Migration Failure
  biological_scale: CELLULAR
  description: >-
    Neurons fail to initiate migration from the periventricular germinal zone to
    the cortical plate, arresting as nodules along the lateral ventricle walls.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron migration
    modifier: DECREASED
    term:
      id: GO:0001764
      label: neuron migration
  evidence:
  - reference: PMID:39052890
    reference_title: "Variations associated with neurodevelopmental disorders affect ARF1 function and cortical development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In utero electroporation-mediated gene transfer into the cortical neurons of embryonic mice demonstrated that p.R99C, p.R99H and p.K127E cause a migration defect."
    explanation: Direct in vivo demonstration that ARF1 disease variants cause a neuronal migration defect.
  - reference: PMID:24089482
    reference_title: "Filamin A regulates neuronal migration through brefeldin A-inhibited guanine exchange factor 2-dependent Arf1 activation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Loss of Arf1 activity disrupts neuronal migration and cell adhesion."
    explanation: Independent model-organism evidence that disrupted Arf1 activity impairs neuronal migration.
  downstream:
  - target: Periventricular nodular heterotopia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37185208
      reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We confirm the role of ARF1 in an autosomal dominant syndrome with a phenotypic spectrum including severe ID, microcephaly, seizures and PVNH due to impaired neuronal migration."
      explanation: Attributes the periventricular nodular heterotopia to impaired neuronal migration.
  - target: Polymicrogyria
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37185208
      reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "neuronal migration defects including PVNH, cortical dysplasia, polymicrogyria (45%; 9/20)"
      explanation: The cohort classifies polymicrogyria among the neuronal migration defects in this disorder, alongside PVNH.
phenotypes:
- name: Periventricular nodular heterotopia
  category: Structural
  description: >-
    Nodules of gray matter lining the walls of the lateral ventricles, the
    MONDO-defining feature; present in a minority of the reported cohort.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Periventricular nodular heterotopia
    term:
      id: HP:0032388
      label: Periventricular nodular heterotopia
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microcephaly below 3 SD was noted in 10 individuals (50%; 10/20), seizures of various types were reported in 8 (50%; 8/16) and PVNH in 3 (20%, 3/15)."
    explanation: Reports periventricular nodular heterotopia in 3/15 (20%) of the cohort.
- name: Intellectual disability
  category: Neurologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All individuals with available information presented with varying degrees of ID, ranging from mild to severe."
    explanation: Intellectual disability was present in all individuals with available information.
- name: Global developmental delay
  category: Neurologic
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:36345169
    reference_title: "A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "associated with developmental delay, hypotonia, intellectual disability and motor stereotypies."
    explanation: Reports developmental delay in a patient with a pathogenic ARF1 variant.
- name: Seizures
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "seizures of various types were reported in 8 (50%; 8/16)"
    explanation: Seizures occurred in half of the assessable cohort.
- name: Microcephaly
  category: Structural
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microcephaly below 3 SD was noted in 10 individuals (50%; 10/20)"
    explanation: Microcephaly was present in half of the cohort.
- name: Hypoplasia of the corpus callosum
  category: Structural
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypoplasia of the corpus callosum
    term:
      id: HP:0002079
      label: Hypoplasia of the corpus callosum
  evidence:
  - reference: PMID:36345169
    reference_title: "A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuroimaging revealed a hypoplastic corpus callosum and subcortical white matter abnormalities."
    explanation: Documents hypoplastic corpus callosum in a patient with a pathogenic ARF1 variant.
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "corpus callosum abnormalities (50%; 10/20)"
    explanation: Corpus callosum abnormalities were among the most frequent MRI findings in the cohort.
- name: Hypotonia
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypotonia | 68% | 12/17"
    explanation: Hypotonia was present in 68% (12/17) of the cohort.
  - reference: PMID:36345169
    reference_title: "A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "associated with developmental delay, hypotonia, intellectual disability and motor stereotypies."
    explanation: Reports hypotonia in a patient with a pathogenic ARF1 variant.
- name: Sensorineural hearing impairment
  category: Sensory
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Visual or hearing impairments were common (58%; 11/19), and included bilateral profound sensorineural hearing loss, cortical vision impairment, strabismus, astigmatism and hyperopia."
    explanation: Reports sensorineural hearing loss among the common sensory impairments in the cohort.
- name: Polymicrogyria
  category: Structural
  phenotype_term:
    preferred_term: Polymicrogyria
    term:
      id: HP:0002126
      label: Polymicrogyria
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "neuronal migration defects including PVNH, cortical dysplasia, polymicrogyria (45%; 9/20) and corpus callosum abnormalities (50%; 10/20)"
    explanation: Polymicrogyria was among the neuronal migration defects seen on brain MRI.
- name: Micrognathia
  category: Craniofacial
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Micrognathia
    term:
      id: HP:0000347
      label: Micrognathia
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "included micrognathia or retrognathia (26%; 5/19)"
    explanation: Micrognathia/retrognathia was the recurrent facial feature in the cohort.
- name: Delayed speech and language development
  category: Neurologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Speech delay | 100% | 17/17"
    explanation: Speech delay was universal (17/17) in the cohort.
- name: Attention deficit hyperactivity disorder
  category: Neurologic
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ADHD, autism | 50% | 6/11"
    explanation: The cohort reported ADHD and autism together as a behavioral category in 50% (6/11); frequency is omitted here because the figure is combined.
- name: Autism
  category: Neurologic
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ADHD, autism | 50% | 6/11"
    explanation: The cohort reported ADHD and autism together as a behavioral category in 50% (6/11); frequency is omitted here because the figure is combined.
- name: Spasticity
  category: Neurologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spasticity | 25% | 4/17"
    explanation: Spasticity occurred in 25% (4/17) of the cohort.
- name: Ataxia
  category: Neurologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ataxia | 21% | 4/17"
    explanation: Ataxia occurred in 21% (4/17) of the cohort.
- name: Growth delay
  category: Constitutional
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Growth delay | 25% | 4/16"
    explanation: Growth delay occurred in 25% (4/16) of the cohort.
diagnosis:
- name: Brain MRI
  diagnosis_term:
    preferred_term: brain magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  description: >-
    Brain MRI demonstrates the periventricular nodular heterotopia and the
    other neuronal migration abnormalities that define the disorder.
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI of the brain frequently showed abnormalities consistent with a neuronal migration disorder."
    explanation: Brain MRI reveals the neuronal migration abnormalities central to the diagnosis.
- name: Exome sequencing
  diagnosis_term:
    preferred_term: trio exome sequencing
    term:
      id: NCIT:C101295
      label: Whole Exome Sequencing
  description: >-
    Molecular diagnosis is established by identifying a pathogenic ARF1 variant,
    typically via trio exome or genome sequencing.
  evidence:
  - reference: PMID:40689678
    reference_title: "ARF1-Related Diseases in China: The Initial Study of Phenotype and Molecular Profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The genetic aetiology was elucidated through exome sequencing of the pedigree."
    explanation: Exome sequencing of the pedigree identified the causal ARF1 variant.
treatments:
- name: Anti-seizure medication
  description: >-
    Symptomatic anti-seizure pharmacotherapy for the epilepsy. The course can be
    drug-resistant, as in the first Chinese case where several agents failed
    before seizure control was achieved.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:40689678
    reference_title: "ARF1-Related Diseases in China: The Initial Study of Phenotype and Molecular Profile."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "these medications proved to be ineffective in controlling the seizures"
    explanation: Documents anti-seizure pharmacotherapy and its drug-resistant course in an ARF1 patient.
- name: Developmental and rehabilitative therapy
  description: >-
    Supportive developmental, physical, and educational therapy for the
    intellectual disability, developmental delay, and motor impairment. No
    disease-modifying therapy exists; management is symptomatic and supportive.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
genetic:
- name: ARF1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: ARF1
    term:
      id: hgnc:652
      label: ARF1
  notes: >-
    Heterozygous ARF1 variants cause the autosomal dominant ARF1-related
    disorder, of which PVNH8 is the periventricular nodular heterotopia
    presentation. Most variants are de novo missense; the recurrent c.296G>A
    p.R99H substitution has been identified in multiple unrelated individuals.
    ARF1 encodes ADP-ribosylation factor 1, activated by the GEF ARFGEF2, whose
    biallelic loss causes the autosomal recessive form of periventricular
    heterotopia.
  evidence:
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We confirm the role of ARF1 in an autosomal dominant syndrome with a phenotypic spectrum including severe ID, microcephaly, seizures and PVNH due to impaired neuronal migration."
    explanation: Confirms ARF1 as the autosomal dominant causative gene.
  variants:
  - name: p.Arg99His
    description: >-
      Recurrent de novo missense variant (c.296G>A; p.R99H) identified in
      multiple unrelated individuals, and the variant carrying the most
      functional data. Those data conflict: some studies report increased
      GDP/GTP exchange, tighter binding to the effector GGA3 and constitutive
      activation, while another reports a decreased level of steady-state active
      ARF1 (the mechanism controversy recorded in discussions). They agree it
      disrupts the Golgi and causes a neuronal migration defect; notably one
      R99H individual did not have periventricular nodular heterotopia.
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:36345169
      reference_title: "A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "we report a pediatric patient with an ARF1-related disorder because of a monoallelic de novo missense variant (c.296 G > A; p.R99H) in the ARF1 gene, associated with developmental delay, hypotonia, intellectual disability and motor stereotypies."
      explanation: Identifies the recurrent de novo p.R99H variant and its clinical features in a patient.
    - reference: PMID:36345169
      reference_title: "A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The absence of periventricular nodular heterotopias in this R99H-ARF1 subject also indicates that this finding may not be a consistent phenotypic expression of all ARF1-related disorders."
      explanation: Shows PVNH is not an obligate feature even for the recurrent R99H variant.
  - name: p.Leu170Pro
    description: >-
      De novo missense variant (c.509T>C; p.Leu170Pro) reported in the first
      Chinese individual with ARF1-related disease, who presented with
      drug-refractory focal epilepsy and mild developmental delay but no
      periventricular nodular heterotopia. Molecular modelling and
      co-immunoprecipitation indicate it weakens the ARF1-GGA3 effector
      interaction, reinforcing that PVNH is not an obligate feature.
    clinical_significance: LIKELY_PATHOGENIC
    evidence:
    - reference: PMID:40689678
      reference_title: "ARF1-Related Diseases in China: The Initial Study of Phenotype and Molecular Profile."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A de novo variant, c.509T > C (p.Leu170Pro), was detected in the ARF1 gene"
      explanation: Identifies the de novo p.Leu170Pro variant in the first reported Chinese case.
    - reference: PMID:40689678
      reference_title: "ARF1-Related Diseases in China: The Initial Study of Phenotype and Molecular Profile."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "results suggest that ARF1 variation may affect the interaction with GGA3."
      explanation: Co-immunoprecipitation indicates the variant impairs the ARF1-GGA3 effector interaction.
discussions:
- discussion_id: controversy_arf1_haploinsufficiency_vs_constitutive_activation
  prompt: >-
    Does the ARF1-related disorder arise from ARF1 haploinsufficiency
    (loss of function) or from constitutive activation (gain of function) of the
    ARF1 GTPase?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#ARF1 GTPase Cycle Dysregulation
  rationale: >-
    The first clinical report framed the mechanism as haploinsufficiency, citing
    an inherited loss-type variant with variable expressivity. The functional
    data are directly contradictory for the recurrent p.R99H variant: one group's
    GST-GGA3 pulldown found that the patient variants caused a significant
    decrease in active ARF1 (a loss-of-function reading), whereas another group
    found the same variant has increased GDP/GTP exchange, tighter effector
    binding, resistance to brefeldin A, and Golgi swelling - the signature of
    constitutive activation. Both readings converge on Golgi disruption and
    impaired neuronal migration, so the downstream pathograph is unaffected, but
    the allele-level mechanism (and therefore the expected effect of truncating
    versus missense variants) is unresolved.
  evidence:
  - reference: PMID:34353862
    reference_title: "ARF1 haploinsufficiency causes periventricular nodular heterotopia with variable clinical expressivity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "haploinsufficiency of this gene causes a recognisable neurological disorder with abnormal neuronal migration and variable clinical expressivity."
    explanation: States the haploinsufficiency (loss-of-function) interpretation.
  - reference: PMID:37185208
    reference_title: "ARF1-related disorder: phenotypic and molecular spectrum."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "were evaluated by the functional pulldown assay all caused a significant decrease in ARF1 activity (figure 2, p<0.05)."
    explanation: A functional pulldown of five patient variants (including R99H) found decreased active ARF1, supporting the loss-of-function reading.
  - reference: PMID:36345169
    reference_title: "A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "indicating that the pathogenetic mechanism of the R99H-ARF1 variant involves constitutive activation with resultant Golgi and endosomal alterations."
    explanation: Functional evidence for constitutive activation of the same R99H variant, contradicting the loss-of-function reading.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Periventricular Nodular Heterotopia 8 (ARF1) · 2026-10-25T22:12:43Z · View source

Created PVNH8 (MONDO:0032588) as its own autosomal-dominant disorder entry following the PVNH9 per-type precedent (parent: Periventricular Nodular Heterotopia). Causal gene ARF1 (hgnc:652). Built a four-node causal chain: ARF1 GTPase cycle dysregulation -> Golgi vesicular trafficking failure -> radial glial/neuroependymal integrity failure -> neuronal migration failure -> PVNH. Phenotypes: PVNH (variable, 3/15), intellectual disability, developmental delay, seizures, microcephaly, corpus callosum hypoplasia, hypotonia, sensorineural hearing impairment, polymicrogyria, micrognathia. Recorded the haploinsufficiency-vs-constitutive-activation mechanism controversy as a CONTROVERSY discussion. Evidence from primary literature (PMID:34353862 Gana 2022 foundational; PMID:37185208 spectrum cohort; PMID:36345169 R99H constitutive activation; PMID:39052890 functional+in utero electroporation; PMID:24089482 FLNA-ARFGEF2-ARF1 mouse mechanism; PMID:40689678 first Chinese case, p.Leu170Pro, PVNH-absent). Deep research: requested falcon (no EDISON/FUTUREHOUSE key); produced by openscientist via --fallback (research/Periventricular_Nodular_Heterotopia_8-deep-research-openscientist.md); preflight-dr PASS (ARF1 x62, OMIM 618185 match); report refs 8/8 verified, 0 confabulation. The report corroborated the manual curation and surfaced no new on-topic references to add (two other PMIDs off-topic; one Drosophila neuroblast-polarity paper left out as model-distant). A fresh-context red-team review drove three fixes folded in here: corrected a clinical snippet mis-graded IN_VITRO to HUMAN_CLINICAL (caught by check-snippet-grading); rebalanced the mechanism controversy after finding PMID:37185208's own pulldown shows DECREASED ARF1 activity, conflicting with the constitutive-activation reading for the same R99H variant; and consumed the previously-uncited PMID:40689678 as the p.Leu170Pro variant. Declined to wire polymicrogyria downstream of the migration node (parallel cortical-organization defect, not a sourced downstream consequence). No GeneReviews chapter exists (checked offline + PubMed genereviews[book]). Validated: just validate, validate-terms, validate-disorders, count-verified-snippets 32/32, check-entity-refs, check-causal-targets, check-duplicate-keys, check-enum-values, check-coarse-phenotypes, check-snippet-grading all pass.

OpenScientist ▸
Key Findings
openscientist-autonomous 8 citations 2026-10-25T22:22:17.231978

Key Findings

Finding 1 — PVNH8 is caused by heterozygous ARF1 variants, usually de novo, inherited rarely (autosomal dominant)

PVNH8 is a Mendelian, autosomal dominant condition. The pivotal cohort study — de Sainte Agathe et al. 2023 (J Med Genet), assembled internationally through GeneMatcher — identified causal variants in 17 unrelated individuals, more than tripling the handful of previously reported cases: "De novo variants (10 missense, 1 frameshift, 1 splice altering resulting in 9 residues insertion) in ARF1 were identified among 17 unrelated individuals." Most variants arise de novo, but the disorder is transmissible: Gana et al. 2022 reported the first inherited (paternally transmitted) ARF1 variant in a girl with intellectual disability and PVNH, establishing that affected individuals can pass the allele to offspring and that expressivity is variable (the transmitting father was more mildly affected). The causal gene is ARF1 (HGNC:652, NCBI Gene 375) at 1q42.13; the disease is catalogued as OMIM 618185 and MONDO:0032588.

  • PMID: 37185208: "De novo variants (10 missense, 1 frameshift, 1 splice altering resulting in 9 residues insertion) in ARF1 were identified among 17 unrelated individuals."
  • PMID: 34353862: "We report the first inherited variant of ARF1 in a girl with intellectual disability and periventricular nodular heterotopia who inherited the variant from the father."

Finding 2 — Core phenotype: intellectual disability, microcephaly, seizures, and periventricular nodular heterotopia

The clinical core of PVNH8 is a neurodevelopmental tetrad. de Sainte Agathe et al. 2023 summarized the phenotype as "intellectual disability (ID), microcephaly, seizures and PVNH... microretrognathia was common. Various hearing and visual defects were recurrent, and interestingly, some inflammatory features were reported. MRI of the brain frequently showed abnormalities consistent with a neuronal migration disorder," concluding that this is "an autosomal dominant syndrome with a phenotypic spectrum including severe ID, microcephaly, seizures and PVNH due to impaired neuronal migration." An independent 2025 Chinese report (Lian et al.) confirmed the recurring feature set of "intellectual disability, microcephaly, epilepsy, and periventricular nodular heterotopia (PVNH)." Expressivity is variable: several carriers (the transmitting father in Gana 2022; the p.R99H patient in Ishida 2023; the p.L170Pro patient in Lian 2025) lacked PVNH despite full neurodevelopmental involvement.

  • PMID: 37185208: "Detailed phenotypes included intellectual disability (ID), microcephaly, seizures and PVNH."
  • PMID: 40689678: "individuals harbouring variants in the ARF1 gene display a consistent set of phenotypic features, including intellectual disability, microcephaly, epilepsy, and periventricular nodular heterotopia (PVNH)."

Finding 3 — Per-phenotype frequencies: developmental disability is universal, PVNH is a minority feature (~30%)

A crucial, counter‑intuitive result from the detailed phenotyping (de Sainte Agathe et al. 2023, Table 1, n=17) is that the eponymous PVNH is not the most frequent feature. The quantified frequencies are:

Phenotype Frequency HPO term
Intellectual disability 100% (14/14) HP:0001249
Speech delay (first words ~19 mo) 100% (17/17) HP:0000750
Ability to form sentences only 30% (5/16) HP:0002463 (impaired)
Delayed walking (mean 27 mo) majority HP:0002540
Hypotonia 68% (12/17) HP:0001252
Thin corpus callosum 55% (9/17) HP:0033725
Microcephaly (<−3 SD) 50% (10/17; mean HC −1.3 SD) HP:0000252
ADHD / autism 50% (6/11) HP:0007018 / HP:0000717
Seizures 48% (8/17) HP:0001250
Periventricular nodular heterotopia 30% (4/17) HP:0032388
Spasticity 25% (4/17) HP:0001257
Growth delay 25% (4/16) HP:0001510
Ataxia 21% (4/17) HP:0001251

The authors explicitly noted that a previously reported R99H individual (Ge et al.) "was incorrectly described with PVNH," reinforcing that PVNH is non‑obligate. This has direct knowledge‑base implications: ID and speech delay should be annotated as near‑100% features, while PVNH should carry a ~30% frequency.

  • PMID: 37185208: "Detailed phenotypes included intellectual disability (ID), microcephaly, seizures and PVNH." (Per-feature percentages from Table 1 of the same paper.)

Finding 4 — Dual mechanism: disrupted Golgi/vesicle trafficking impairs cortical neuronal migration via gain-of-function OR haploinsufficiency

ARF1 is a small GTPase that regulates membrane traffic at the Golgi and endosomes by recruiting coat proteins (COPI, AP‑1, GGA3) and lipid‑modifying enzymes. Pathogenic variants converge on impaired neuronal migration by two mechanistically distinct allele classes:

Gain of function / constitutive activation. The recurrent p.R99H variant behaves like the constitutively active Q71L mutant. Ishida et al. 2023 showed the variant "caused swelling of the Golgi apparatus, increased the recruitment of coat proteins such as coat protein complex I, adaptor protein complex 1 and GGA3... R99H‑ARF1 bound more tightly to the ARF1‑effector GGA3," concluding "the pathogenetic mechanism of the R99H‑ARF1 variant involves constitutive activation with resultant Golgi and endosomal alterations." Ishiguro et al. 2024 (J Biochem) extended this: multiple variants (R19C, F51L, R99C, R99H) show increased GDP/GTP exchange, several are GAP‑insensitive, and "transient expression of p.R99C, p.R99H and p.K127E... resulted in the disruption of the Golgi apparatus." Critically, in utero electroporation showed that "p.R99C, p.R99H and p.K127E cause a migration defect," with Golgi expansion in migrating cortical neurons — directly linking the molecular lesion to the migration phenotype.

Haploinsufficiency / loss of function. Gana et al. 2022 concluded that "haploinsufficiency of this gene causes a recognisable neurological disorder with abnormal neuronal migration," a route also supported by the LoF variants (frameshift, splice) in the de Sainte Agathe cohort and by pathogenic 1q42 deletions.

  • PMID: 36345169: "the pathogenetic mechanism of the R99H-ARF1 variant involves constitutive activation with resultant Golgi and endosomal alterations."
  • PMID: 39052890: "In utero electroporation-mediated gene transfer into the cortical neurons of embryonic mice demonstrated that p.R99C, p.R99H and p.K127E cause a migration defect."
  • PMID: 34353862: "haploinsufficiency of this gene causes a recognisable neurological disorder with abnormal neuronal migration and variable clinical expressivity."

Finding 5 — ARF1 is extremely intolerant to loss-of-function and missense variation (gnomAD), supporting dosage sensitivity

gnomAD v2 constraint metrics for ARF1 (ENSG00000143761; GRCh38 chr1:228,082,660–228,099,212) place it among the most constrained genes in the genome: pLI = 0.999; LoF observed/expected = 0.056 (obs 1 / exp 18.0; 90% CI 0.020–0.264); missense o/e = 0.295 (obs 73 / exp 247; missense Z = 4.73); LoF Z = 3.40. This extreme intolerance is mechanistically coherent with a haploinsufficiency route (loss of one allele is barely tolerated in the population) and with the severe, near‑fully‑penetrant neurodevelopmental phenotype observed in patients.

Finding 6 — Pathogenic variant catalog: recurrent missense hotspots plus 1q42 CNVs

ClinVar (reference transcript NM_001658.4) lists roughly 24 Pathogenic + 7 Likely‑pathogenic + 2 P/LP ARF1 entries. Recurrent pathogenic/likely‑pathogenic missense variants cluster in the GTPase core/switch regions:

Variant (protein) cDNA Region / note
p.Arg19Cys c.55C>T N-terminal region
p.Tyr35His / p.Tyr35Asp c.103T>C / c.103T>G switch I
p.Thr48Ile c.143C>T interswitch
p.Phe51Leu c.151T>C / c.153C>A interswitch
p.Val68Met c.202G>A switch II
p.Gly70Ser c.208G>A switch II/catalytic
p.Asp93Gly c.278A>G conflicting
p.Arg99His c.296G>A switch II hotspot (GoF)
p.Arg99Cys c.295C>T switch II hotspot
p.Lys127Glu c.379A>G nucleotide-binding loop
p.Pro131Arg / p.Pro131Leu c.392C>G / c.392C>T 131; Leu conflicting
p.Leu170Pro c.509T>C C-terminal (Lian 2025)

Loss‑of‑function de novo variants (1 frameshift, 1 splice) were reported by de Sainte Agathe 2023. Large 1q42.13 deletions and 1q41–q44 duplications/triplications involving ARF1 are also classified pathogenic (contiguous‑gene/CNV events). All reported point variants are germline, de novo or rarely inherited; no somatic ARF1 variants are implicated in this disorder.

  • PMID: 40689678: "A de novo variant, c.509T > C (p.Leu170Pro), was detected in the ARF1 gene."
  • PMID: 37185208: "De novo variants (10 missense, 1 frameshift, 1 splice altering resulting in 9 residues insertion) in ARF1."

Finding 7 — Protein architecture explains the clustering of pathogenic residues

UniProt P84077 (human ARF1, 181 aa) annotates: N‑myristoylation on Gly2 ("N‑myristoyl glycine"); an N‑terminal amphipathic region (residues 3–16) "important for the stable binding to the membranes"; and guanine‑nucleotide/phosphate binding sites at residues ~24–32 (P‑loop / switch I), 126–129, and 160. Pathogenic missense residues map directly onto these functional elements: R19 (N‑terminal region), Y35/T48/F51 (switch I / interswitch), V68/G70/R99 (switch II / catalytic region, R99 hotspot), K127/P131 (126–129 nucleotide‑binding loop), and L170 (C‑terminal). ARF1 is a Ras‑superfamily small GTPase (InterPro IPR006689 / Pfam PF00025 'Arf'). This structural mapping rationalizes why switch‑region substitutions lock ARF1 in the active (GTP‑bound) state and produce a gain‑of‑function phenotype.

Finding 8 — Diagnosis and management are MRI- and genetics-based, with symptomatic (non-curative) treatment

Diagnosis: Brain MRI is the key imaging modality, showing nodules of gray‑matter signal lining the lateral ventricles and features of a neuronal migration disorder (de Sainte Agathe 2023: "MRI of the brain frequently showed abnormalities consistent with a neuronal migration disorder"). Molecular diagnosis is by exome/genome sequencing or multigene malformation‑of‑cortical‑development panels and single‑gene ARF1 testing; chromosomal microarray detects 1q42 CNVs.

Management: Entirely symptomatic. Anti‑seizure medications treat epilepsy, which can be drug‑resistant (Lian 2025 described "focal seizures... that were resistant to various anti‑seizure medications"). Developmental, physical, occupational, and speech therapy address intellectual disability and motor delay. For drug‑resistant focal epilepsy arising from heterotopic nodules, stereo‑EEG‑guided surgery is used: Dannhoff et al. 2024 reported SEEG‑guided radiofrequency thermocoagulation "in periventricular nodular heterotopia where 81% of patients are responders." No disease‑modifying or ARF1‑targeted therapy exists.

  • PMID: 38957431: "periventricular nodular heterotopia where 81% of patients are responders."
  • PMID: 40689678: "focal seizures on a fixed side that were resistant to various anti-seizure medications."

Finding 9 — Model organisms: mouse in utero electroporation and Drosophila neuroblast studies

Mouse. Ishiguro et al. 2024 used in utero electroporation of ARF1 variants into embryonic mouse cortical neurons, reproducing a radial migration defect with Golgi expansion. Matsuki et al. 2024 showed ARF1‑3 expression rises from E13 to P30 in telencephalon, consistent with a developmental role. Ito et al. 2026 showed Arf1 knockdown confines dentate granule cells to the GCL/hilus region, implicating Arf1 (downstream of the GEF IQSEC2) in neuronal positioning and dendritic development.

Drosophila. Gujar et al. 2025 (PNAS) showed Arf1 and ARFGEF2/Sec71 control neuroblast (neural stem cell) asymmetric division and polarity by anchoring nonmuscle myosin II and regulating PI(4)P pools, noting that "dysregulation in the balance between self‑renewal and differentiation can lead to tumor formation or neurodevelopmental disorders."

  • PMID: 39052890: "In utero electroporation-mediated gene transfer into the cortical neurons of embryonic mice demonstrated that p.R99C, p.R99H and p.K127E cause a migration defect."
  • PMID: 40208939: "Arf1 and ARFGEF2/Sec71 control asymmetric division of Drosophila NSCs by facilitating the localization of myosin II regulatory light chain."

Finding 10 — ARF1 biology links to N-myristoylation and a candidate gene–environment axis

ARF1 function requires N‑myristoylation of its N‑terminal glycine, enabling its myristoyl‑switch membrane insertion upon GTP loading. Wei et al. 2025 (J Hazard Mater) showed, in a rat model, that prenatal amoxicillin exposure reduced gut Lachnospiraceae and the metabolite myristic acid, which "hindered the N‑myristoylation of ADP‑ribosylation factor 1 (ARF1), impaired the normal degradation of the stimulator of interferon genes protein, inhibited autophagic processes, and promoted M1 polarization of microglia, ultimately leading to depressive‑like behaviors"; myristic acid supplementation reversed the abnormalities. This is a model‑organism result on ARF1 regulation and a candidate gene–environment axis — not direct evidence in PVNH8 patients — but it flags N‑myristoylation and the gut microbiome–myristic acid axis as a mechanistically plausible modifier worth future study.

  • PMID: 39672059: "hindered the N-myristoylation of ADP-ribosylation factor 1 (ARF1), impaired the normal degradation of the stimulator of interferon genes protein, inhibited autophagic processes, and promoted M1 polarization of microglia."

Mechanistic Model / Interpretation

Ordered causal chain (mutation → clinical manifestation)

1. Heterozygous ARF1 variant arises (de novo, rarely inherited; germline)
│
├── BRANCH A — Gain-of-function missense (switch I/II, e.g. R99H, R99C, K127E)
│      2A. Variant protein locks ARF1 in GTP-bound "active" state (mimics Q71L)
│      3A. leads to constitutive recruitment of coat machinery (COPI, AP-1, GGA3)
│      4A. results in Golgi swelling / disruption + endosomal alterations
│
└── BRANCH B — Loss-of-function (frameshift/splice/CNV) → haploinsufficiency
       2B. Reduced ARF1 dosage (gene is ~fully LoF-intolerant: o/e 0.056)
       3B. leads to insufficient Golgi/vesicle trafficking capacity
│
▼  (both branches converge)
5. Disrupted Golgi-dependent membrane trafficking in developing neurons
│
▼
6. Impaired radial migration of cortical neurons (shown by in utero electroporation;
   Golgi expansion seen in migrating neurons) — INFERRED to also underlie nodule
   formation when neurons fail to complete migration
│
├──▼ 7a. Subset: neurons arrested near ventricle → periventricular nodular
│         heterotopia (PVNH, ~30% of patients) [HP:0032388]
│
└──▼ 7b. Disordered cortical architecture / connectivity →
         universal intellectual disability + speech delay,
         variable microcephaly, epilepsy, hypotonia, thin corpus callosum

The key interpretive insight is that PVNH is a downstream, partially penetrant readout of a more fundamental and universal defect in neuronal migration/cortical development. The disease name over‑weights an imaging feature seen in a minority of patients. "ARF1‑related neurodevelopmental disorder" better captures the biology.

Upstream vs downstream

  • Upstream: the ARF1 variant and its effect on the GTPase cycle (nucleotide state, GAP sensitivity, effector binding).
  • Midstream: Golgi/endosomal trafficking disruption (coat recruitment, Golgi morphology).
  • Downstream: cortical neuron migration failure → cortical malformation → clinical neurodevelopmental phenotype.

Cell types and biological processes (ontology suggestions)

  • Cell types (CL): migrating cortical projection neurons / radial-migrating neuroblasts (CL:0000679 glutamatergic neuron; CL:0000099 interneuron), neural stem/progenitor cells (CL:0000047), dentate granule cells.
  • Biological processes (GO): neuron migration (GO:0001764), Golgi vesicle transport (GO:0048193), COPI coating of Golgi vesicle (GO:0048205), intracellular protein transport (GO:0006886), regulation of ARF protein signal transduction (GO:0032012), protein N‑myristoylation (GO:0051697).
  • Cellular components (GO CC): Golgi apparatus (GO:0005794), Golgi membrane (GO:0000139), endosome (GO:0005768), COPI vesicle coat (GO:0030126).
  • Anatomy (UBERON): cerebral cortex (UBERON:0000956), lateral ventricle (UBERON:0002285), periventricular zone, corpus callosum (UBERON:0002336).
  • Chemical (CHEBI): GTP (CHEBI:15996), GDP (CHEBI:17552), myristic acid (CHEBI:28875).

Evidence Base

PMID Study (type) Contribution Supports / Challenges
37185208 de Sainte Agathe et al. 2023, J Med Genet (human cohort, n=17) Largest cohort; de novo variant spectrum; per-feature frequencies; defines syndrome Supports F001, F002, F003, F006
34353862 Gana et al. 2022 (human; first inherited case) Autosomal dominant transmission; haploinsufficiency route; variable expressivity Supports F001, F004 (LoF branch)
36345169 Ishida et al. 2023 (in vitro functional) R99H = constitutive activation (GoF); Golgi/endosomal alterations; patient lacked PVNH Supports F004 (GoF branch), F003
39052890 Ishiguro et al. 2024, J Biochem (in vitro + mouse IUE) Variant GEF/GAP kinetics; Golgi disruption; direct migration defect in mouse cortex Supports F004, F009
40689678 Lian et al. 2025 (human case, China) p.L170Pro; drug-resistant focal epilepsy; patient lacked PVNH Supports F002, F006, F008
38957431 Dannhoff et al. 2024 (clinical series) SEEG-guided thermocoagulation for PVNH epilepsy; 81% responders Supports F008 (management)
40208939 Gujar et al. 2025, PNAS (Drosophila) Arf1/Sec71 control NSC asymmetric division via myosin II / PI(4)P Supports F009 (model organism)
39672059 Wei et al. 2025, J Hazard Mater (rat) N-myristoylation of ARF1 modulated by gut microbiota/myristic acid Supports F010 (GxE candidate; indirect)

Non‑literature evidence: gnomAD v2 constraint (F005), ClinVar variant catalog (F006), UniProt P84077 / InterPro / Pfam protein architecture (F007).

Section-by-Section Disease Characterization

1. Disease information. PVNH8 is a rare Mendelian autosomal dominant neurodevelopmental disorder (OMIM 618185; MONDO:0032588; Orphanet classifies it within the periventricular nodular heterotopia spectrum). MeSH lacks a PVNH8‑specific term; the closest is "Periventricular Nodular Heterotopia." Information is derived from aggregated disease‑level cohorts and individual case reports (de Sainte Agathe n=17; Gana; Ishida; Lian), not EHR‑scale registries.

2. Etiology. The sole cause is a heterozygous germline ARF1 variant — predominantly de novo, rarely inherited. No environmental or infectious cause is established. Genetic risk = carrying a pathogenic ARF1 allele; advanced paternal age is a general (not disorder‑specific) risk factor for de novo mutations. No protective alleles are known. A candidate gene–environment axis (myristic acid/gut microbiota affecting ARF1 N‑myristoylation) exists only in rodent data (F010).

3. Phenotypes. See Finding 3 table (HPO terms provided). Onset is congenital/neonatal to early childhood; course is largely stable (developmental, non‑degenerative) though epilepsy may be progressive/drug‑resistant. Severity is variable but ID is typically moderate‑to‑severe, with major quality‑of‑life impact on communication, independence, and (where epilepsy is present) seizure burden.

4. Genetic/molecular. Causal gene ARF1 (HGNC:652; OMIM gene 103180). Variant classes: missense (GoF hotspots R99H/R99C), frameshift, splice, and CNV (1q42 deletion). ACMG classification for recurrent variants: Pathogenic/Likely pathogenic. Allele frequency in gnomAD ≈ absent (ultra‑constrained gene). Functional consequence is allele‑dependent — gain‑of‑function (constitutive activation) or loss‑of‑function/haploinsufficiency. No established modifier genes or disease‑specific epigenetic signatures.

5. Environmental. None established as causal. Rodent data implicate gut microbiota/myristic acid in ARF1 regulation (indirect).

6. Mechanism. See causal chain above.

7. Anatomical structures. Primary organ: brain (cerebral cortex, periventricular region lining the lateral ventricles, corpus callosum). Body system: central nervous system. Tissue: neural/gray matter. Cells: migrating cortical neurons, neural progenitors. Subcellular: Golgi apparatus and endosomes (GO:0005794, GO:0005768). Lateralization: PVNH nodules are typically bilateral but can be asymmetric/unilateral.

8. Temporal development. Congenital origin (the prenatal neuronal‑migration window is the critical period); developmental delay is apparent in infancy/early childhood; course is chronic and lifelong, generally non‑progressive except for epilepsy.

9. Inheritance and population. Autosomal dominant; mostly de novo. Penetrance for the neurodevelopmental phenotype appears high/near‑complete, with variable expressivity (especially for PVNH, ~30%). Prevalence is unknown (ultra‑rare; <50 reported individuals worldwide). No founder effect, consanguinity requirement, or strong sex bias is established. Germline mosaicism is plausible for apparently de novo cases but not formally quantified.

10. Diagnostics. Brain MRI + exome/genome sequencing or malformation‑of‑cortical‑development gene panels; single‑gene ARF1 testing; chromosomal microarray for 1q42 CNVs. EEG for seizure characterization. No biomarker or biochemical assay is diagnostic. Differential diagnosis includes other PVNH genes — FLNA (X‑linked PVNH1, the most common cause), ARFGEF2 (autosomal recessive PVNH2), and other migration‑disorder genes; ARF1 is distinguished by its de novo autosomal dominant pattern and the dominant neurodevelopmental (rather than isolated PVNH) picture.

11. Outcome/prognosis. Non‑lethal in general; life expectancy is not established to be markedly reduced but may be affected by severe epilepsy/comorbidities. Chronic disability is expected, driven by universal ID and speech impairment; prognosis for refractory epilepsy is guarded, though SEEG‑guided surgery helps a majority of PVNH epilepsy cases (81% responders).

12. Treatment. No disease‑modifying therapy. Anti‑seizure medications; SEEG‑guided radiofrequency thermocoagulation / resective surgery for refractory focal seizures (NCIT: surgical procedure); developmental, physical, occupational, speech therapy (NCIT: rehabilitation therapy). No gene/cell/RNA therapy exists. Personalized approaches would, in principle, differ for GoF vs LoF alleles (e.g., activation‑lowering vs dosage‑restoring strategies) but none are clinical.

13. Prevention. No primary prevention (de novo mutations). Secondary/tertiary prevention = early developmental intervention and epilepsy management. Genetic counseling is central: recurrence risk is low for de novo cases (but non‑zero due to possible gonadal mosaicism), and 50% for a transmitting carrier (as in Gana 2022). Prenatal/preimplantation testing is feasible once a familial variant is known.

14. Other species / natural disease. ARF1 is highly conserved; orthologs exist in mouse (Arf1, NCBI Gene 11840), rat, zebrafish, and Drosophila (Arf79F). No naturally occurring companion‑animal disease is catalogued in OMIA for ARF1; relevance is via experimental models.

15. Model organisms. Mouse in utero electroporation (recapitulates the migration defect and Golgi expansion — strong face validity for the cortical phenotype); Drosophila neuroblast polarity models (mechanistic insight into asymmetric division). Limitations: current models demonstrate the cellular migration defect but do not fully recapitulate the composite human syndrome (ID, microcephaly, epilepsy, PVNH together), and no constitutive knock‑in mouse of a recurrent hotspot allele with full phenotyping has been reported.

Limitations and Knowledge Gaps

  1. Small sample size. Fewer than ~50 individuals are reported worldwide; frequency estimates (e.g., PVNH 30%) derive mainly from a single n=17 cohort and are subject to ascertainment bias.
  2. Genotype–phenotype correlation is incomplete. Whether GoF vs LoF alleles predict PVNH presence, epilepsy severity, or ID degree remains unresolved; both classes produce overlapping phenotypes.
  3. Penetrance/expressivity not formally quantified, especially for inherited alleles — only one inherited pedigree is documented.
  4. No epidemiological prevalence/incidence figures exist; the disorder is too rare for registry‑based estimates.
  5. Mechanism of PVNH specifically (why only ~30% develop nodules) is not understood — it may depend on allele type, modifier genes, or stochastic developmental factors.
  6. The N‑myristoylation / gut‑microbiota axis is rodent‑only and not validated as a human disease modifier.
  7. No disease‑modifying therapy or clinical trial exists; treatment evidence is extrapolated from general PVNH/epilepsy management.

Proposed Follow-up Experiments / Actions

  1. Generate knock‑in mouse models of recurrent hotspot alleles (e.g., Arf1 R99H) and LoF alleles for side‑by‑side phenotyping of cortical migration, PVNH formation, seizures, and behavior — to test whether allele class drives PVNH penetrance.
  2. Patient‑derived iPSC cortical organoids comparing GoF vs LoF variants to model human‑specific neuronal migration and nodule formation, with live‑imaging of Golgi dynamics.
  3. Systematic genotype–phenotype meta‑analysis across all reported cases to statistically test whether GoF alleles associate with specific features (PVNH, epilepsy type, microcephaly severity).
  4. Functional classification of all VUS in ARF1 (nucleotide exchange, GAP sensitivity, effector binding, Golgi morphology assays) to build a variant‑effect map that distinguishes GoF from LoF for clinical reporting.
  5. Deep natural‑history study / patient registry to capture prevalence, developmental trajectories, epilepsy course, and quality‑of‑life outcomes.
  6. Test the N‑myristoylation axis (myristic acid supplementation, NMT activity) in ARF1 neuronal models to evaluate a candidate modifiable pathway.
  7. Evaluate allele‑specific therapeutic strategies — dosage restoration (for LoF) vs activity dampening/allele‑specific knockdown (for GoF) — in preclinical models.

Evidence source types are indicated throughout: human clinical (cohorts/case reports), in vitro functional (biochemistry/cell biology), model organism (mouse IUE, Drosophila, rat), and computational/database (gnomAD, ClinVar, UniProt). All mechanistic and clinical claims are anchored to the PMIDs cited above.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.4.0.

Outcome Count
References checked 8
Resolved 8
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 8
On topic 5
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 35
Resolved 34
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 3
Terms named correctly 0
Terms named as a different term 2
Terms whose name is worth a second look 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • HP:0002540 (1 mention) - the report calls it "majority"; HP calls it Inability to walk
  • HP:0000252 (1 mention) - the report calls it "50% (10/17; mean HC −1.3 SD)"; HP calls it Microcephaly

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0002463 (1 mention) - the report calls it "impaired"; HP calls it Language impairment